Context Therapeutics (NASDAQ:CNTX) Stock Rating Reaffirmed by HC Wainwright

Context Therapeutics (NASDAQ:CNTX)‘s stock had its “buy” rating reissued by HC Wainwright in a report issued on Monday, Benzinga reports. They presently have a $6.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 189.86% from the stock’s previous close.

Context Therapeutics Trading Down 8.4 %

Shares of NASDAQ:CNTX traded down $0.19 during trading on Monday, reaching $2.07. The stock had a trading volume of 71,196 shares, compared to its average volume of 300,470. The firm’s 50-day simple moving average is $2.31 and its 200 day simple moving average is $1.88. Context Therapeutics has a one year low of $0.77 and a one year high of $2.75. The company has a market capitalization of $155.25 million, a P/E ratio of -1.56 and a beta of 2.31.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.04. Equities research analysts forecast that Context Therapeutics will post -0.31 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC grew its holdings in Context Therapeutics by 63.4% during the 2nd quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock valued at $131,000 after buying an additional 25,300 shares during the last quarter. Opaleye Management Inc. acquired a new position in shares of Context Therapeutics in the 4th quarter worth approximately $1,102,000. Affinity Asset Advisors LLC lifted its holdings in shares of Context Therapeutics by 392.4% in the 2nd quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock worth $3,246,000 after purchasing an additional 1,290,323 shares during the last quarter. Ally Bridge Group NY LLC boosted its position in shares of Context Therapeutics by 159.8% during the second quarter. Ally Bridge Group NY LLC now owns 1,886,232 shares of the company’s stock worth $3,782,000 after buying an additional 1,160,281 shares during the period. Finally, Nantahala Capital Management LLC acquired a new stake in Context Therapeutics in the second quarter worth approximately $3,881,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.